US patent infringement investigation targets German drug price control measures

Eoin Ryan

Tue, June 23, 2026 astatine 4:53 AM CDT 5 min read

The Office of the US Trade Representative (USTR) has triggered a caller progressive probe targeting Germany implicit what it describes arsenic "persistent underpayment for innovative medicines" and different policies discriminatory to US commerce. Underpinning the probe is simply a long-standing condemnation wrong the Trump medication that the US shoulders a disproportionate stock of planetary R&D costs for innovative medicines portion Europe takes vantage of comparatively debased prices for branded pharmaceuticals.

The USTR determination to unfastened a Section 301 probe into pharmaceutical pricing and reimbursement policies successful Germany is portion of an escalating signifier of US enforcement orders piling unit connected European governments to judge higher medicine prices arsenic demanded by the Trump administration. USTR caput Jamieson Greer declared that the probe would absorption connected allegations of "persistent underpayment for innovative pharmaceutical products" by Germany and different "freeloading" policies, which are considered "unreasonable oregon discriminatory" to the US. If investigators uncover violations, this could alteration the USTR to prosecute unilateral enactment against Germany. Options connected the array would perchance see US tariffs oregon import restrictions connected Germany. But since it would beryllium hard for the US to see tariff-related actions connected German imports alone, determination is simply a hazard of broader commercialized implications for the EU.

The trigger for the USTR probe appears chiefly to beryllium implicit fast-tracked German reforms to trim spending connected innovative pharmaceuticals. But the Section 301 probe volition besides measure whether Germany's AMNOG-derived nett prices effect successful "persistent" and "insufficient" payments for innovative pharmaceutical products.

Greer describes the cost-containment proposals emanating from Berlin arsenic representing a "serious measurement backwards" that threatens to trim spending connected innovative medicines. For its part, Germany's Health Minister Nina Warken said that the country's statutory wellness security strategy faces a "strained fiscal situation", which makes it hard to wage higher prices. To code this, German policymakers had projected introducing dynamic discounts connected patent-protected medicines. However, wide absorption wrong Germany had already fixed emergence to credible reports that the struggling conjugation authorities of Chancellor Friedrich Merz was considering abandoning oregon heavy modifying that plan. Whether the US involution accelerates a determination to soften the betterment proposals is debatable. But successful theory, the German authorities would person clip to code US concerns earlier Section 301 hearings instrumentality spot successful September 2026. On the different hand, determination is nary motion of Germany wavering successful its absorption to pharmaceutical terms increases. Germany has offered the US further talks, though Merz billed this arsenic a accidental to supply an mentation of the organisation of the wellness security and cause reimbursement strategy successful Germany to the US executive. Already facing a enactment situation of assurance successful his government, it would beryllium precise hard for Merz to beryllium seen making concessions to the US. Therefore, unsurprisingly, helium has held the enactment that the issues identified by the Section 301 probe are an interior argumentation substance and that the question of tariffs has been dealt with by the EU–US commercialized agreement.